Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study - Lung Cancer
Promising Treatments Boost Positive Extended Results in HCC - U.S. Medicine
IMpower150 Clinical Trial Results | TECENTRIQ® (atezolizumab)
Avastin® (bevacizumab) Clinical Trials | MRCC Treatment
Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma | American Journal of Neuroradiology
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Oncology
Cancers | Free Full-Text | Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
Dose-dependent efficacy of bevacizumab in recurrent glioblastoma | Journal of Neuro-Oncology
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Overall survival according to continuation or discontinuation of... | Download Scientific Diagram
Overall survival and progression-free survival by hyper | Open-i
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial | International
Progression-free survival and overall survival of patients treated with... | Download Scientific Diagram
![PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1f2882819a61e3853acfa2fdb64e9ae4bb6b3252/5-Figure2-1.png "PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar")
PDF] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Semantic Scholar
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | Journal of Neuro-Oncology
New Treatment Options for Colorectal Cancer
Overall survival and time to treatment failure for patients eligible... | Download Scientific Diagram
News Articles | ESMO
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC - Medical Conferences
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study - ScienceDirect
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer | NEJM
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
